UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037781
Receipt number R000043087
Scientific Title Effect of exercise therapy combined with hyperthermia on blood BDNF concentration in healthy young men
Date of disclosure of the study information 2019/08/23
Last modified on 2020/08/24 13:49:23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of exercise therapy combined with hyperthermia on blood BDNF concentration in healthy young men

Acronym

Development of exercise therapy to increase BDNF

Scientific Title

Effect of exercise therapy combined with hyperthermia on blood BDNF concentration in healthy young men

Scientific Title:Acronym

Effect of exercise therapy combined with hyperthermia on blood BDNF concentration in healthy young men

Region

Japan


Condition

Condition

young healthy men

Classification by specialty

Not applicable

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To clarify the immediate effect of exercise therapy combined with hyperthermia on blood BDNF concentration in healthy young men.

Basic objectives2

Others

Basic objectives -Others

It has been reported that long-term exercise (10 weeks or longer) increases blood BDNF at rest with certainty, and a consensus has been reached. However, the exercise method and exercise load which surely increase blood BDNF by the execution of one time exercise have not been clarified, and it is unclear. In the healthy subject, the time over 30 minutes is required at the load over about 70% of the maximum oxygen intake, but the clinical application is difficult for the elderly and the person with the disability after the disease because the load is high. In order to enable clinical application, it is necessary to establish a single exercise method in which blood BDNF increases surely while exercise load quantity and exercise time are decreased.

Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Serum and plasma brain-derived neurotrophic factor (BDNF; brain-derived neurotrophic factor) immediately after 15 minutes of warm bath exercise therapy

Key secondary outcomes

Plasma cortisol, lactic acid, Serum S 100 .BETA., neuron-specific enolase (NSE; neuron-specificenolase), Irisin, P selectin (CD 62 P), CBC (CBC; complete blood count), central temperature (esophageal temperature), blood pressure, heart rate, perceived exertion (Borg Scale), water temperature


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

Bicycle ergometer (60% of maximal oxygen uptake) 15 minutes in subjugated water at 40'C

Interventions/Control_2

40'C, subjugated water 15 minutes

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

39 years-old >=

Gender

Male

Key inclusion criteria

1.20-30age
2.a person able to communicate (No cognitive or higher brain dysfunction)
3.Those who wish to participate voluntarily

Key exclusion criteria

Persons with diabetes mellitus, heart disease, chronic inflammatory disease, or skin disease.

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Umemoto
Middle name
Last name Yasunori

Organization

Wakayama Medical University

Division name

rehabilitation medicine

Zip code

6418509

Address

811-1 Kimiidera, Wakayama City

TEL

073-441-0664

Email

yumemoto@wakayama-med.ac.jp


Public contact

Name of contact person

1st name Ohko
Middle name
Last name Hiroshi

Organization

Wakayama Medical University

Division name

rehabilitation medicine

Zip code

6418509

Address

811-1 Kimiidera, Wakayama City

TEL

073-441-0664

Homepage URL


Email

ohko-h@seijoh-u.ac.jp


Sponsor or person

Institute

Wakayama Medical University

Institute

Department

Personal name



Funding Source

Organization

Wakayama Medical University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Wakayama Medical University Ethics Review Committee

Address

811-1 Kimiidera, Wakayama City

Tel

073-447-2300

Email

wa-rinri@wakayama-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 08 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

10

Results

The serum BDNF concentration significantly increased immediately after the HOI-ex task and remained significantly increased 15 min after the task.
No changes in serum BDNF concentration were observed during the HOI experiment.
Comparison of the serum BDNF concentration HOI and HOI-ex tasks showed higher concentrations after the HOI-ex task than after the HOI task, and the difference was statistically significant.

Results date posted

2020 Year 08 Month 24 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events

None.

Outcome measures

Plasma cortisol, lactic acid, Serum S 100 .BETA., neuron-specific enolase (NSE; neuron-specificenolase), Irisin, P selectin (CD 62 P), CBC (CBC; complete blood count), central temperature (esophageal temperature), blood pressure, heart rate, perceived exertion (Borg Scale), water temperature

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 08 Month 23 Day

Date of IRB

2019 Year 08 Month 30 Day

Anticipated trial start date

2019 Year 09 Month 16 Day

Last follow-up date

2022 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 08 Month 23 Day

Last modified on

2020 Year 08 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043087


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name